{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:24:59Z","timestamp":1783088699188,"version":"3.54.6"},"reference-count":7,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Dear Editor,\nIncreased prevalence of cancer, in particular lymphomas, has been observed in patients with multiple sclerosis (MS) treated with fingolimod. We report the first case of primary cutaneous marginal zone lymphoma (PCMZL) that developed under longterm fingolimod therapy for MS. [...]<\/jats:p>","DOI":"10.4081\/dr.2025.10237","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T14:57:20Z","timestamp":1752245840000},"source":"Crossref","is-referenced-by-count":0,"title":["Primary cutaneous marginal zone lymphoma in a patient with multiple sclerosis under fingolimod therapy"],"prefix":"10.4081","volume":"18","author":[{"given":"Thilo","family":"Gambichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sera Selina","family":"Weyer-Fahlbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Schade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieselotte","family":"Bissels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Susok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"41041","doi-asserted-by":"crossref","unstructured":"1. Askari M, Mirmosayyeb O, Ghaffary EM, et al. Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis. Mult Scler Relat Disord 2022;59:103680.","DOI":"10.1016\/j.msard.2022.103680"},{"key":"41042","doi-asserted-by":"crossref","unstructured":"2. Wills A, Fan G, Kim E, et al. Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod. Dermatol Online J 2019;25:13030\/qt2g62q2fq.","DOI":"10.5070\/D3259045508"},{"key":"41043","doi-asserted-by":"crossref","unstructured":"3. Connolly A, Grandi V, Stefanato CM, et al. Primary cutaneous CD30+ anaplastic large-cell lymphoma associated with fingolimod. Br J Dermatol 2018;179:1400-1.","DOI":"10.1111\/bjd.17003"},{"key":"41044","doi-asserted-by":"crossref","unstructured":"4. Froehlich A, Schmidt S, Landsberg J, et al. Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. Mult Scler 2018;24:1785-7.","DOI":"10.1177\/1352458518774444"},{"key":"41045","doi-asserted-by":"crossref","unstructured":"5. Soma L, Crisan L, Reid J, et al. Epstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature. Am J Clin Pathol 2024:aqae124.","DOI":"10.1093\/ajcp\/aqae124"},{"key":"41046","doi-asserted-by":"crossref","unstructured":"6. Stitt DW, Boes CJ, Flanagan EP, et al. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler Relat Disord 2018;19:115-7.","DOI":"10.1016\/j.msard.2017.11.014"},{"key":"41047","doi-asserted-by":"crossref","unstructured":"7. Awada Z, Hameed N, Harel A. Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. Drug Des Devel Ther 2024;18:5985-96.","DOI":"10.2147\/DDDT.S315174"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10237\/9702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10237\/9963","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10237\/9702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:14:55Z","timestamp":1783088095000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,11]]}},"URL":"https:\/\/doi.org\/10.4081\/dr.2025.10237","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}